

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

EZH2-human

RRID:AB_10694683

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5246, RRID:AB_10694683

Antibody Information

URL: http://antibodyregistry.org/AB_10694683

Proper Citation: Cell Signaling Technology Cat# 5246, RRID:AB_10694683

Target Antigen: EZH2

Host Organism: rabbit

Clonality: unknown

Comments: ENCODE PROJECT External validation DATA SET is released testing lot 2 for any cell type or tissues; status is awaiting lab characterization; this is from 5246BF Consolidated with RRID:AB_2616026 and RRID:AB_10831048 on 07/25/16
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: EZH2-human

Description: This unknown targets EZH2

Target Organism: homo sapiens

Antibody ID: AB_10694683

Vendor: Cell Signaling Technology

Catalog Number: 5246

Alternative Catalog Numbers: 5246BF, 5246P, ENCAB350TQZ, 5246S

Record Creation Time: 20231110T034925+0000

Record Last Update: 20260831T221239+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 2 is available under ENCODE ID: ENCAB350TQZ - ENCODE
<https://www.encodeproject.org/antibodies/ENCAB350TQZ>

No alerts have been found for EZH2-human.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 164 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Vargas C, et al. (2026) The TRIP12's intrinsically disordered region induces chromatin condensates and interferes with nuclear processes. *iScience*, 29(2), 114592.

Niekamp S, et al. (2026) Mutual antagonism between PRC1 condensates and SWI/SNF in chromatin regulation. *Molecular cell*, 86(9), 1673.

Nocente MC, et al. (2026) Poising and connectivity of emergent human developmental enhancers in the transition from naive to primed pluripotency. *Cell reports*, 45(6), 117402.

Zhou Y, et al. (2026) ERK1/2 function as a central hub safeguarding primed human embryonic stem cell identity via multifaceted regulatory networks. *Cell reports*, 45(7), 117675.

Agius SC, et al. (2026) Accessory subunits of PRC2 mimic H3K27me3 to restrict the spread of Polycomb domains. *Molecular cell*, 86(6), 1032.

Chen Z, et al. (2026) Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. *Cell reports. Medicine*, 7(4), 102712.

Kuser-Abali G, et al. (2026) Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP. *Molecular cell*, 86(13), 2521.

Cheng R, et al. (2026) Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21- and OTUD4-mediated EZH2 ubiquitination. *British journal of pharmacology*, 183(11), 2675.

Purohit TA, et al. (2026) Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. *Neoplasia (New York, N.Y.)*, 73, 101289.

Hanley SE, et al. (2026) Cyclin C promotes pancreatic development and suppresses cancer initiation by maintenance of the autophagy-lysosome pathway. *iScience*, 29(3), 114949.

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. *Cancer discovery*, 16(1), 135.

Huang Y, et al. (2026) Sequence-dependent splicing dysregulation drives therapy resistance in pediatric AML. *Cell reports. Medicine*, 7(1), 102542.

Cmarik EA, et al. (2026) Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation. *Molecular cancer research : MCR*, 24(7), 555.

Liu SS, et al. (2026) Epigenetic regulation of NDGA and its synergistic inhibition with EZH2 inhibitors in prostate cancer via NRP1. *Acta pharmacologica Sinica*, 47(6), 1643.

Foidart P, et al. (2026) Whole-genome doubling drives immune evasion by silencing antigen presentation. *Cancer cell*, 44(7), 1418.

Chennakesavalu M, et al. (2026) 5-hydroxymethylcytosine deposition mediates Polycomb repressive complex 2 function in MYCN-amplified neuroblastoma. *iScience*, 29(8), 116816.

Kim H, et al. (2026) Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin. *Molecular cell*, 86(14), 2739.

Zhu Y, et al. (2026) Single cell CRISPR screen identifies antagonism between Nsd1-H3K36me2 and Ezh2-H3K27me3 orchestrates pluripotency transition. *Stem cell reports*, 103016.

Fujisawa S, et al. (2025) The transcription factor BATF pioneers the differentiation program of effector CD8⁺ T cells through the interaction with IRF4. *Cell reports*, 44(8), 116129.

Debbache J, et al. (2025) A novel murine model for sporadic, malignant peripheral nerve sheath tumors, driven by BrafV600E and Pten loss. *Disease models & mechanisms*, 18(11).